KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Enterprise Value: 2017-2025

Historic Enterprise Value for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to $428.4 million.

  • Aquestive Therapeutics' Enterprise Value rose 14.06% to $428.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.7 million, marking a year-over-year increase of 36.61%. This contributed to the annual value of $253.0 million for FY2024, which is 127.98% up from last year.
  • Latest data reveals that Aquestive Therapeutics reported Enterprise Value of $428.4 million as of Q3 2025, which was up 59.71% from $268.2 million recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Enterprise Value peaked at $428.4 million during Q3 2025, and registered a low of $9.1 million during Q2 2022.
  • Moreover, its 3-year median value for Enterprise Value was $217.1 million (2024), whereas its average is $199.5 million.
  • Per our database at Business Quant, Aquestive Therapeutics' Enterprise Value tumbled by 91.79% in 2022 and then skyrocketed by 665.67% in 2023.
  • Aquestive Therapeutics' Enterprise Value (Quarterly) stood at $128.2 million in 2021, then tumbled by 83.17% to $21.6 million in 2022, then soared by 414.33% to $111.0 million in 2023, then soared by 127.98% to $253.0 million in 2024, then grew by 14.06% to $428.4 million in 2025.
  • Its Enterprise Value was $428.4 million in Q3 2025, compared to $268.2 million in Q2 2025 and $218.1 million in Q1 2025.